【摘要】 目的 探讨肺炎患儿使用脾氨肽联合雾化吸入治疗对其免疫功能的影响及临床疗效。方法 以盐城市第一人民医院于2021年7月—2022年7月收治86例儿童肺炎患儿为研究对象，随机分为观察组与对照组，每组43例，其中对照组采取吸入用布地奈德混悬液雾化治疗，观察组在对照组基础联合上脾氨肽口服治疗，对比两组治疗前、治疗1个月后儿童肺炎患儿免疫功能及临床疗效。结果 观察组临床疗效（93.02%）高于对照组（76.74%），差异有统计学意义（P<0.05）；治疗前，两组免疫功能指标比较差异不明显，治疗1个月后，均改善，且观察组患儿CD4+、CD4+/CD8+显著高于对照组，观察组CD8+、免疫球蛋白E显著低于对照组，差异有统计学意义（P<0.05）。治疗1个月后，两组患者白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)水平明显降低观察组较对照组低（P<0.05）；两组血清干扰素-γ(IFN-γ)水平均高于治疗前，且观察组高于对照组（P<0.05）。结论 应用脾氨肽联合雾化吸入法治疗儿童肺炎，能有效改善临床疗效、提高免疫水平，抑制炎性因子，对治疗儿童性肺炎具有一定积极意义。更多还原

【Abstract】 Objective To explore clinical effect of splenic peptide combined with nebulized inhalation therapy for immune function of children with pneumonia. Methods The paper chose 86pediatric pneumonia patients admitted to Yancheng City the First People’s Hospital from July 2021to July 2022, and divided them into observation group and control group randomly, with 43 cases in each group. Control group was treated with inhalation of budesonide suspension nebulization,while observation group with oral treatment with splenic peptide on the basis of control group.Immune function and clinical effect between two groups was compared before and after one month of treatment. Results Clinical effect of observation group(93.02%) was higher than control group(76.74%),with statistically significant difference(P<0.05). After 1 month of treatment, both groups of patients showed a significant increase in CD4+(Cluster Of Differentiation 4) and CD4+/CD8+ levels, with the observation group having higher values than the control group. Additionally, the observation group exhibited significantly lower CD8+(Cluster Of Differentiation 8) and Immunoglobulin E(IgE) levels compared to the control group(P < 0.05). After one month of treatment, interleukin 6(IL-6) and tumor necrosis factor-α(Tumor Necrosis Factor, TNF-α)levels significantly decreased in two groups, those of observation group were lower than control group at the same time. Serum interferon-γ(IFN-γ)level was higher than before treatment, that of observation group was higher than control group at the same time(P<0.05). Conclusion Combination of splenic aminopeptide and nebulized inhalation therapy can effectively improve clinical effect, increase immune levels, inhibit inflammatory factors of for pediatric pneumonia, which has some certain positive significance in treatment of pediatric pneumonia.更多还原